None" title="" class="btn" data-container="body" data-html="true" data-id="424167" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#b3d4fc" tabindex="0" data-original-title="OMass Therapeutics"> 592 6,485
Activities
Technologies
Entity types
Location
Chancellor Court, John Smith Dr, Oxford Business Park, Oxford OX4 2GX, UK
Oxford
United Kingdom
Employees
Scale: 11-50
Estimated: 82
Engaged corporates
14Added in Motherbase
1 year, 9 months agoOMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Other 7 Sep 2020 | | |
![]() Bayer Pharmaceutical, Chemistry, Chemical Manufacturing | Bayer Pharmaceutical, Chemistry, Chemical Manufacturing | Other 2 Aug 2019 | | |
![]() EU Green Capital European Union, Environmental Services | EU Green Capital European Union, Environmental Services | Other 8 May 2019 | | |
![]() Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 20 Sep 2024 | |